Black Diamond Therapeutics, Inc. · NASDAQ:BDTX
Vestal Point Capital, LP's stake in Black Diamond Therapeutics, Inc. fell to 1.50% (Schedule 13G/A)
Event Dec 31, 2025 · Filed Feb 17, 2026
Vestal Point Capital, LP's stake in Black Diamond Therapeutics, Inc. fell to 1.50%, 870,000 shares, as a passive investor on Dec 31, 2025. Filed Feb 17, 2026 (Schedule 13G/A).
- Stake
- 1.50%
- Shares
- 870,000
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 2 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Vestal Point Capital, LP | 1.50% | 870,000 |
| Ryan Wilder | 1.50% | 870,000 |
Source
Related
- Black Diamond Therapeutics, Inc.
- Vestal Point Capital, LP
- Black Diamond Therapeutics, Inc. shareholders
- Form 4 · Behbahani Ali · Sep 21, 2026
- Form 4 · Raman Prakash · Sep 21, 2026
- Schedule 13G · BlackRock, Inc. · Jul 27, 2026
- Schedule 13G/A · T. Rowe Price Investment Management, Inc. · Jul 8, 2026
- Form 4 · Behbahani Ali · Jun 22, 2026